Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

UCSF Chimera—A visualization system for exploratory research and analysis

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 46,047

Coot : model-building tools for molecular graphics

Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571

Phaser crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612

MolProbity : all-atom structure validation for macromolecular crystallography

Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677

RELION: Implementation of a Bayesian approach to cryo-EM structure determination

Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446

How good are my data and what is the resolution?

Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743

Comparative Protein Structure Modeling Using MODELLER

Webb, B., & Šali, A. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.3 · Cited by 4,404

PHENIX : building new software for automated crystallographic structure determination

Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361

ConSurf 2016: An improved methodology to estimate and visualize evolutionary conservation in macromolecules

Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163

A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors

Wang, Q., McManus, L. R., Levine, K. S., Blanc, R., Malca, H., Joughin, B. A., Bi, C., Keerti, K., Lauffenburger, D. A., Wesemann, D. R., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag106 · Cited by 1

Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit

Zhou, L., Hsieh, C., Leist, S. R., Miller, E. H., Horton, A. P., Shoemaker, S. R., Gardner, E. C., Powers, J. M., Boutz, D. R., Mallory, M. L., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014391 · Cited by 1

Inducing Quality Immune Response to Respiratory Viruses May Not Be a Simple Task

Ranga, U., & Asokan, M. (2021) · Current Science · doi:10.18520/cs/v120/i8/1315-1323 · Cited by 1

An Overview: the types of Covid-19 vaccines in Iraq

Hamza, H. J., Maaroof, R. J., Hindi, N. K. K., Shalan, A. A., & Yasir, A. A. (2022) · Journal of University of Babylon for Pure and Applied Sciences · doi:10.29196/jubpas.v30i1.4169 · Cited by 1

Analyzing the Impermeable Structure and Myriad of Antiviral Therapies for SARS-CoV-2

Jose, A. M., & Muntode, P. (2022) · Journal of the Association of Physicians of India · doi:10.5005/japi-11001-0140 · Cited by 1

A genetically engineered, stem-cell-derived cellular vaccine

Cooper, A., Sidaway, A., Chandrashekar, A., Latta, E., Chakraborty, K., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100843 · Cited by 1

Inhibition of Main Protease of SARS-CoV-2 Using Brahmi Plant (Bacopa Monnieri) Compound by Computational Screening

Islam, M. A., Asaduzzaman, M., Hossain, M. F., & Alam, M. T. (2022) · International Conference on Recent Progresses in Science, Engineering and Technology (ICRPSET) · doi:10.1109/icrpset57982.2022.10188556 · Cited by 1

A Candidate DNA Vaccine Encoding the Native SARS-CoV-2 Spike Protein Induces Anti-Subdomain 1 Antibodies

Frische, A., Gunalan, V., Krogfelt, K. A., Fomsgaard, A., & Lassaunière, R. (2023) · Vaccines · doi:10.3390/vaccines11091451 · Cited by 1

Cryo-Electron Microscopy and Cryo-Electron Tomography of Viruses

Luque, D., & Castón, J. R. (2023) · Springer series in biophysics · doi:10.1007/978-3-031-36815-8_12 · Cited by 1

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291972 · Cited by 1

A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern

Abdulal, R. H., Khan, M. Y., Aljehani, N. D., Fallata, Z. I., Alharbi, R. H., Alsulaiman, R. M., Ghazal, E. A., Basabrain, M. A., Sanki, M. A., Ganash, M., et al. (2023) · Transboundary and Emerging Diseases · doi:10.1155/2023/5279979 · Cited by 2

Mammalian Antigen Display for Pandemic Countermeasures

Quezada, A., Annapareddy, A., Javanmardi, K., Cooper, J., & Finkelstein, I. J. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3666-4_12 · Cited by 1

Nobel Prize in physiology or medicine 2023: Development of mRNA therapeutics that paved the path of formulation of COVID-19 vaccine

Mandal, N. (2024) · Journal of Hematology and Allied Sciences · doi:10.25259/jhas_4_2024 · Cited by 1

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46714-w · Cited by 1

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model

Brunet, J., Choucha, Z., Gransagne, M., Tabbal, H., Ku, M., Buchrieser, J., Fernandes, P., Batalie, D., Lopez, J., Ma, L., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01693-23 · Cited by 1

A novel approach to designing viral precision vaccines applied to SARS-CoV-2

Trabelsi, K., Khalaf, N. B., Ramadan, A. R., Elsharkawy, A., Ashoor, D., Chlif, S., Boussoffara, T., Ahmed, M. B., Kumar, M., & Fathallah, M. D. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1346349 · Cited by 1

Immunomodulatory properties of Leishmania tarentolae extracellular vesicles containing the Spike protein of SARS-CoV-2

Medina, A. C., Ospina, H. A., & Descoteaux, A. (2024) · Frontiers in Parasitology · doi:10.3389/fpara.2024.1306478 · Cited by 1

The biology of neutralizing antibody therapy with REGEN-COV

Sasaki, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00013-5 · Cited by 1

Conventional Electron Microscopy, Cryogenic Electron Microscopy, and Cryogenic Electron Tomography of Viruses

Castón, J. R., & Luque, D. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-65187-8_3 · Cited by 1

Lethal Human Coronavirus Infections and the Role of Vaccines in Their Prevention

Baldwin, J., & Petrovsky, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-71165-8_24 · Cited by 1

Advances in vaccination to combat pandemic outbreaks

Dasari, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85662-1.00002-1 · Cited by 1

COVID-19 mRNA Vaccines

Yau, Y., Mishra, S., Easterling, M., & Kumar, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-9001-3_31 · Cited by 1

Structure-Based Design of Recombinant Spike Subunit Vaccine for Coronavirus Diseases

Mahmuda, M., Jannah, S. A., Fibriani, A., Ningrum, R. A., & Wardiana, A. (2023) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.13.1.16202 · Cited by 1

Stalking new vaccines: Methods that target the stems of viral proteins could put universal vaccines within reach

Arnold, C. (2017) · Nature Medicine · doi:10.1038/nm1117-1248 · Cited by 1

Receptor binding and proteolysis do not induce large conformational changes in the SARS-CoV spikePreprint

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrel, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.2210/pdb6cs1/pdb · Cited by 1

A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in micePreprint

Frantz, P. N., Barinov, A., Ruffié, C., Combredet, C., Najburg, V., Teeravechyan, S., Jongkaewwattana, A., Prot, M., Conquet, L., Montagutelli, X., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.17.431630 · Cited by 1

Synthetic protein antigens for COVID-19 diagnosticsPreprint

Schein, C. H., Levine, C. B., McLellan, S., Negi, S. S., Braun, W. A., Dreskin, S. C., Anaya, E. S., & Schmidt, J. G. (2021) · medRxiv · doi:10.1101/2021.02.23.21251934 · Cited by 1

Algorithm for the Quantitation of Variants of Concern for Rationally Designed Vaccines Based on the Isolation of SARS-CoV-2 Hawaiʻi Lineage B.1.243Preprint

Maison, D. P., Ching, L. L., Cleveland, S. B., Tseng, A. C., Nakano, E. T., Shikuma, C. M., & Nerurkar, V. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.18.455536 · Cited by 1

Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint

Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · doi:10.22541/au.162615692.26217047/v2 · Cited by 1

Intranasal Immunization with a Proteosome-Adjuvanted SARS-CoV2 Spike Protein-Based Vaccine is Immunogenic and Efficacious in Mice & HamstersPreprint

Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.482651 · Cited by 1

Broad neutralization of SARS-CoV-2 variants by circular mRNA producing VFLIP-X spike in micePreprint

Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484759 · Cited by 1

Free Energy Landscapes for RBD Opening in SARS-CoV-2 Spike Glycoprotein Simulations Suggest Key Interactions and a Potentially Druggable Allosteric PocketPreprint

Fallon, L., Belfon, K. A. A., Raguette, L. E., Wang, Y., Corbo, C. P., Stepanenko, D., Cuomo, A. E., Guerra, J., Budhan, S., Varghese, S., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13502646 · Cited by 1

Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 InfectionPreprint

Ismail Yilmaz, C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Aydin, Y., Guvencli, N., Gungor, B., et al. (2021) · doi:10.22541/au.162615692.26217047/v1 · Cited by 1

Simultaneous and sequential multi-species coronavirus vaccinationPreprint

Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.07.491038 · Cited by 1

Catching the breadth of broadly protective antibodies to SARS-CoV-2

McCarthy, K. R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01225-y · Cited by 1

Development and application of an uncapped mRNA platformPreprint

Zheng, X., Liu, B., Ni, P., Cai, L., Shi, X., Ke, Z., Zhang, S., Hu, B., Yang, B., Xu, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.05.494796 · Cited by 1

Rational Vaccine Design for SARS-CoV-2 Virus—A Systematic ReviewPreprint

Ghosh, A., Pavlović, M. D., & Larrondo-Petrie, M. M. (2023) · Preprints.org · doi:10.20944/preprints202311.1607.v1 · Cited by 1

Antigen-display exosomes provide adjuvant-free protection against SARS-CoV-2 disease at nanogram levels of spike proteinPreprint

Guo, C., Sachithanandham, J., Zhong, W., Craney, M. C., Villano, J., Pekosz, A. S., & Gould, S. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574272 · Cited by 1

Selectomic and Evolvability Analyses of the Highly Pathogenic Betacoronaviruses SARS-CoV-2, SARS-CoV, and MERS-CoV

May, M. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3756936 · Cited by 1

Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation

Morais, P., & Yu, Y. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch3 · Cited by 2

Design and Development of mRNA Vaccines to Combat the COVID ‐19 Pandemic

Tombácz, I. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch8 · Cited by 1

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated micePreprint

Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.18.670983 · Cited by 1

Twelve-month follow-up of immunogenicity and safety of fractional and standard booster doses of the Pfizer-BioNTech COVID-19 vaccine in adults primed with ChAdOx1, BBIBP-CorV, or GAM-CoV-Vac: a randomised controlled trialPreprint

Batmunkh, T., Neal, E. F. G., Amraa, O., Mazarakis, N., Altangerel, B., Avaa, N., Batbayar, L., Batsukh, K., Bright, K., Burentogtokh, T., et al. (2025) · medRxiv · doi:10.1101/2025.08.29.25334703 · Cited by 1

Structural Definition of Neutralizing Epitopes within and around the HKU1 Receptor-binding Site Reveals Cell Context–Dependent NeutralizationPreprint

Joseph, J., Wang, L., Vasquez, S., Su, C.-M., Wrapp, D., Rosen, O., Abiona, O. M., Dzuvor, C. K. O., Kirchdoerfer, R. N., Moak, S. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.29.685445 · Cited by 1

Unconventional linkers facilitate potent stabilized coronavirus stem antibody responses following nanoparticle vaccinationPreprint

Dzuvor, C. K. O., Moak, S. P., McManus, L. R., Dzordzorme, A. E., Evanson, L. R., Kim, T., Thomas, A., Adeyemi, O., Foley, V., Limaye, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.19.689216 · Cited by 1

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated micePreprint

Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959 · Cited by 1

Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to virus escapePreprint

CLARKE, J., Jones, L. M., Buckle, I., Sharma, P., Park, E., Kipar, A., Kirby, A., Mega, D. F., Ramadurai, S., Karmakar, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.08.698330 · Cited by 1

Protective pan-betacoronavirus neutralizing antibodies by vaccinationPreprint

Zhou, P.-P., Feng, Z., He, W.-T., Zhu, Y., Yuan, M., Li, X., Zhang, Y., Vo, L., Capozzola, T., Callaghan, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743418 · Cited by 1

Comparative Genomics of Receptor Binding Domains of Spike Protein and Receptor Interaction in COVID-19 PatientPreprint

Dasgupta, R. (2020) · doi:10.21467/preprints.118

Model of trigger mechanisms of SARS CoV-2 infections

Galarza, N. C., & Condori, M. D. L. Á. M. (2020) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20203478

Peer Review #3 of "Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach (v0.2)"

(2020) · PeerJ · doi:10.7287/peerj.9572v0.2/reviews/3

Peer Review #3 of "Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9572v0.1/reviews/3

Peer Review #1 of "Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9689v0.1/reviews/1

Development of COVID-19 vaccines: A race against time!

Bhatia, M., & Rohilla, R. (2020) · Journal of Patient Safety & Infection Control · doi:10.4103/jpsic.jpsic_6_20

Peer Review #2 of "Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease (v0.2)"

(2020) · PeerJ · doi:10.7287/peerj.9689v0.2/reviews/2

Peer Review #2 of "Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9689v0.1/reviews/2

Peer Review #3 of "Genomic diversity and evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9689v0.1/reviews/3

Prepandemic Preparedness under the Spotlight at ASGCT’s COVID-19 Symposium

Dolgin, E. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.004

COVID19: Exploring uncommon epitopes for a stable immune response through MHC1 bindingPreprint

Abitogun, F., Srivastava, R., Sharma, S., Komarysta, V., Akurut, E., Munir, N., Macalalad, L. S., Olawale, O., Owolabi, O., Abayomi, G. O., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.14.339689

SARS ve MERS aşılarının gizemi, Coronavirus aşısına yeni yaklaşımlar

Şimşek, A., & Avcı, O. (2020) · Eurasian journal of veterinary sciences · doi:10.15312/eurasianjvetsci.2020.295

Vacunas contra COVID19. Una carrera contra el tiempo

Sáez‐Llorens, X. (2020) · Revista médica de Panamá · doi:10.37980/im.journal.rmdp.20201715

Why would a Black man volunteer for a government-funded science experiment?

Nduom, E. K.-E. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100788

Altered O-glycosylation Level of SARS-CoV-2 Spike Protein by Host O-glycosyltransferase Strengthens Its Trimeric StructurePreprint

Xu, Z., Ku, X., Tian, J., Zhang, H., Hou, J., Zhang, C., Shi, J., Yang, L., Kaji, H., Tao, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438614

Potential Molecular Players Against to SARS-CoV-2: A Glyco-Perspective

Tugrul, B., Balcan, E., & Öztel, Z. (2021) · Journal of Cell Biology and Histology · doi:10.15744/2638-082x.4.101

Star-shaped molecules cross-bind to SARS-CoV2 spike α-helices in silicoPreprint

Coll, J. M. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-xb6sx

T Cell Predominant Response to AAV-Spike Protects hACE2 Mice from SARS-CoV-2 PneumoniaPreprint

Greer, C. D., Kasden, C. M., Morales, L., Lundgreen, K. A., Hicks, P. D., Carpenter, L. J., Salas-Quinchucua, C., Tichy, E. D., Maguire, A. M., Hoffman, J. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.16.456441 · Cited by 1

COVID-19: Vaccines on Their Marks

Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888

Comparative Analysis Between SARS-CoV, MERS-CoV, and SARS-CoV-2: Genomic Similarity, Spike Protein Homology, and Government Funding as it Relates to Vaccine Development

Foresman, B. (2021)

Review: A 3.4-Å cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles — R0/PR2

(2020) · QRB Discovery · doi:10.1017/qrd.2020.16.pr2

A guide on how to work in vaccine science

Fleming, N. (2021) · Nature · doi:10.1038/d41586-021-03056-7

Review: A 3.4-Å cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles — R0/PR1

(2020) · QRB Discovery · doi:10.1017/qrd.2020.16.pr1

Fuente de conflictos

Atienza, J. E. (2006) · Temas para el debate

Prise d'acte et préavis - Les arrêts du 20 janvier 2010.

Couturier, G. (2010) · Droit social

A Novel CRISPR-Engineered, Stem Cell-Derived Cellular VaccinePreprint

Chakraborty, K., Chandrashekar, A., Sidaway, A., Latta, E., Yu, J., McMahan, K., Giffin, V. M., Manickam, C., Kroll, K. W., Mosher, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.28.474336

A Focus on Severe Acute Respiratory Syndrome ( SARS ) Coronavirus ( SARS‐CoVs ) 1 and 2

Cannalire, R., Tramontano, E., & Summa, V. (2021) · Methods and principles in medicinal chemistry · doi:10.1002/9783527810697.ch17

A REVIEW ON THE COMMON THREAT WORLDWIDE: CORONAVIRUS DISEASE (COVID-19)

(2021) · International Journal of Biology Pharmacy and Allied Sciences · doi:10.31032/ijbpas/2021/10.12.5748

Vaccines’ Candidates Against SARS-CoV-2

ISI-SENAI-CIMATEC Group (2020) · Journal of Bioengineering, Technologies and Health · doi:10.34178/jbth.v3i2.126

Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2Preprint

Dou, C., Qin, C., Wang, L., Song, D., Deng, Y., Wang, W., Dong, C., Ning, Z., Liu, X., Liu, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-141793/v1

A review of leading COVID-19 vaccines, the quest for immune protection, and its key challenges. Part 3: Covid-19 vaccines – Key challenges and translational sciencePreprint

Hartshorne, J., & Villiers, P. J. T. D. (2021) · AfricArXiv (OSF Preprints) · doi:10.31730/osf.io/e7udq

Decision: A 3.4-Å cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles — R0/PR3

(2020) · QRB Discovery · doi:10.1017/qrd.2020.16.pr3

Decision: A 3.4-Å cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles — R1/PR4

(2020) · QRB Discovery · doi:10.1017/qrd.2020.16.pr4

Decision: A 3.4-Å cryo-EM structure of the human coronavirus spike trimer computationally derived from vitrified NL63 virus particles — R2/PR5

(2020) · QRB Discovery · doi:10.1017/qrd.2020.16.pr5

In silico screening of known small molecules to bind ACE2 specific RBD on Spike Glycoprotein of SARS-CoV-2 for repurposing against COVID-19Preprint

Bharath, B. R., Damle, H., Ganju, S., & LathaDamle (2020) · doi:10.21203/rs.3.rs-28557/v1

Peer Review #2 of "Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9572v0.1/reviews/2

Would It Be Possible to Stabilize Prefusion SARS-COV-2 Spikes with Ligands?Preprint

Lorenzo, M. M., Blasco, R., & Coll, J. M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13453919

Peer Review #1 of "Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach (v0.1)"

(2020) · PeerJ · doi:10.7287/peerj.9572v0.1/reviews/1

Coronaviruses

Louten, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90565-7.00014-9

Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2

Mathew, B. J., Gupta, S., Nema, R. K., Vyas, A. K., Khare, P. S., Biswas, D., & Singh, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00019-4

Identification of Highly Potent Transmission-Blocking Human Monoclonal Antibodies to Plasmodium falciparum Pfs230 in Naturally Exposed IndividualsPreprint

Ivanochko, D., Fabra-García, A., Teelen, K., van de Vegte‐Bolmer, M., van Gemert, G., Newton, J. C., Semesi, A., de Bruijni, M. H. C., Bolscher, J. M., Ramjith, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4199639

Propriété industrielle et recherche fondamentale dans la genèse du vaccin ARNm contre la COVID-19

Migus, A. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.06.014

[Progress on the development of the SARS-CoV-2 vaccine and antibody drugs].

Xu, S.-Y., & Tang, D. (2022) · PubMed Central · doi:10.7507/1001-5515.202207063

Pandemics and the English Language: Concepts Critical for Conversing About COVID-19

Greenspan, N. S., & Pereda, G. A. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.542

The World ChangedTHE COVID‐19 PANDEMIC

(2022) · Wiley eBooks · doi:10.1002/9781683673828.ch10

Caught in the Act: targeted mutagenesis of the herpesvirus fusogen central helix captures transition statesPreprint

Zhou, M., Vollmer, B., Machala, E. A., Chen, M., Grünewald, K., Arvin, A. M., Chiu, W., & Oliver, S. L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.23.517751

Secondary conformation of MERS-CoV, SARS-CoV and SARS-CoV-2 Spike Proteins revealed by Infrared Vibrational SpectroscopyPreprint

D’Arco, A., Fabrizio, M. D., Mancini, T., Mosetti, R., Macis, S., Tranfo, G., Ventura, G. D., Marcelli, A., Petrarca, M., & Lupi, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2245843/v1

Schnelle und sichere Impfstoffe gegen potenziell pandemische Viren – können wir uns darauf verlassen?

Rohde, C., & Becker, S. (2022) · Springer eBooks · doi:10.1007/978-3-662-66073-7_11

Applications of genetic engineering in COVID-19

Ysrafil, Y., Pratiwi, S. E., & Cornillot, E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91794-0.00021-4

Vaccines

Sellers, R. S., & Nelson, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00029-4

Test

Injeti, N. (2022) · International Journal of Experimental and Biomedical Research · doi:10.26452/ijebr.v1i3.382

Important Structural Insights of the 2019-nCoV Spike Protein

Hossain, M. M. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.17.002386

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

Walls, A. C., Xiong, X., Park, Y.-J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.028 · Cited by 582

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms15092 · Cited by 756

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein

Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., Wang, Q., Lu, X., Wu, Y., Liu, W., et al. (2015) · Cell Research · doi:10.1038/cr.2015.113 · Cited by 150

Single-molecule imaging prefusion intermediate conformations of MERS-CoV spike trimers in membrane during entry

Dey, S., Pahari, P., Shukla, M., Andrabi, R., & Das, D. K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115916 · Cited by 4

The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections

Jang, T., Park, W.-J., Lee, H., Woo, H., Lee, S., Kim, K.-C., Kim, S. S., Hong, E., Song, J., & Lee, J.-Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-05318-4 · Cited by 5